Erectile dysfunction following treatments of benign prostatic hyperplasia: A prospective study

Andrologia

Volumn 30, Issue 1, 1998, Pages 5-10

  Uygur, M C ^a,b   Gur E ^a   Ank, A I ^a   Altug U ^a   Erol, D ^a  

^a ANKARA NUMUNE HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

Benign prostatic hyperplasia; Medical; Sexual function; Surgical; Treatment

Indexed keywords

DOXAZOSIN; FINASTERIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MALE; PENIS DISEASE; PENIS ERECTION; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; PROSTATECTOMY; SEXUAL FUNCTION; TRANSURETHRAL RESECTION; VAPORIZATION;

EID: 0031923827     PISSN: 03034569     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1439-0272.1998.tb01375.x     Document Type: Article

References (26)

1. Andersson S, Russel DW (1990) Structural and biochemical properties of cloned and expressed human and rat 5 α-reductase. Proc Natl Acad Sci USA 87:3640-3644.
2. Bary MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgreve HL, Mebust WK, Cocket ATK and the Measurement Committee of the American Urological Association (1992) The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 148:1549-1557.
3. Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474-479.
4. Christ CJ (1995) The penis as a vascular organ. The importance of corporal smooth muscle tone in the control of erection. Urol Clin North Am 22:727-745.
5. Cunningham GR, Hirshkowitz M (1995) Inhibition of steroid 5 α-reductase with finasteride: sleep related erections, potency, and libido in healthy men. J Clin Endocrinol Metab 80:1934-1940.
6. Cytron S, Simon D, Segenreic E, Lieb Z, Sevadio C (1987) Changes in the sexual behaviour after prostatectomy. Eur Urol 13:35-38.
7. Davidson JM, Camargo CA, Smith ER (1979): Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab 48:955-958.
8. Giuliano FA, Rampin O, Benoit G, Jardin A (1995) Neural control of penile erection. Urol Clin North Am 22:747-766.
9. Kaiser FE (1991) Sexuality and impotence in the aging man. Clin Geriatr Med 7:63-72.
10. Kaplan SA, Te AE (1995) Transurethral electrovaporization of the prostate: a novel method for treating men with benign prostatic hyperplasia. Urology 45:566-572.
11. Kirby RS (1996) Doxazosin: Safety relative to other medical therapies for benign prostatic hyperplasia. Eur Urol 29 (suppl 1):24-30.
12. Koeghane SR, Doll HA, Lawrence KC, Jenkinson CP, Cranston DW (1996) The Oxford laser prostate trial: sexual function data from a randomised controlled clinical trial of contact laser prostatectomy. Eur Urol 30:424-428.
13. Lepor H, Kaplan SA, Klimberg I, Mobley DF, Fawzy A, Gaffney M, Ice K and Dias N for the multicenter study group (1997) Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. J Urol 157:525-530.
14. Lue TF (1990) Impotence after prostatectomy. Urol Clin North Am 17:613-620.
15. Oesterling JE (1995) Benign prostatic hyperplasia: medical and minimally invasive treatment options. N Engl J Med 332:99-109.
16. O'Leary MP, Fowler FJ, Lenderking WR, Barber B, Sagnier PP, Guess HA, Bary MJ (1995) A brief male sexual function inventory for urology. Urology 46:697-706.
17. Perlmutter AP, Muschter R, Razvi HA (1995) Electrosurgical vaporization of the prostate in the canine model. Urology 46:518-523.
18. Samdal F, Vada K, Lundmo P (1993) Sexual function after transurethral prostatectomy. Scand J Urol Nephrol 27:27-29.
19. Schiavi RC, Rehman J (1995) Sexuality and aging. Urol Clin North Am 22:711-726.
20. Seyam RM, Huynh HT, Bégin LR, Rittmaster RS, Macramalla AN, Abdelbaky TM, Dion SB, Brock GB (1997). 5 α reductase inhibition induces a biphasic regulatory response in transcription of neuronal and endothelial nitric oxide synthase: new insights into the role of androgenic control of erection. J Urol 157 (Suppl): A 1389.
21. Soderdahl DW, Knight RW, Hansberry KL (1996) Erectile dysfunction following transurethral resection of the prostate. J Urol 156:1354-1356.
22. Tammela TLJ, Kontturi M (1995) Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia. J Urol 154:1466-1469.
23. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnel JD, Russel DW (1993) Tissue distribution and ontogeny of steroid 5 α-reductase isozyme expression. J Clin Invest 92:903-910.
24. Vermeulen A, Giagulli VA, De Schepper P, Buntinx A (1991) Hormonal effects of a 5α-reductase inhibitor (finasteride) on hormonal levels in normal and in patients with benign prostatic hyperplasia. Eur Urol 20(Suppl 2):82-86.
25. Wilton L, Pearce G, Edet E, Freemantle S, Stephens MDB, Man RD (1996) The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14772 patients. Br J Urol 78:379-384.
26. Witjes WPJ, De Wildt JAM, Rosier PFWM, Caris CTM, Debruyne FMJ, De La Rosette JMCH (1996) Variability of clinical and pressure-flow study variables after 6 months of watchful waiting in patients with lower urinary tract symptoms and benign prostatic enlargement. J Urol 156:1026-1034.